UBS Gives a Buy Rating to Skeena Resources (SKE)

UBS analyst Daniel Major assigned a Buy rating to Skeena Resources (SKE) with a C$60.00 price target. The average analyst consensus is Moderate Buy with a C$56.00 target. Skeena reported a Q2 GAAP net loss of C$35.22 million, slightly improved from last year's C$36.03 million loss. Insider sentiment is negative, with increased selling activity.

Original reporting
Published Aug 26, 2026, 8:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 6:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
UBS Gives a Buy Rating to Skeena Resources (SKE) — source image
Decision brief

The 30-second read

Med
01

Why it matters

The rating provides a fresh catalyst for the stock, which could trigger buying pressure.

02

Market read

Analyst upgrade may influence trading activity in the mining sector.

03

What to watch

Potential dilution from future financing needs.

Relevance 7/10Novelty 7/10Timing: today

Background

UBS analyst Daniel Major covers basic materials and issued a new Buy rating for Skeena Resources.

Market effects

May lift sentiment in the basic materials sector.

Limited to Canadian mining stocks.

Low

Counterpoint

Insider selling suggests caution despite the upgrade.

Key entities

  • Skeena Resources

    Canadian mining company listed on TSX.

  • UBS

    Investment bank providing the analyst rating.

Related articles

$NEMMed

Ottawa’s $500M Red Chris bet tests BC grid

Ottawa will contribute C$500M (US$352M) to Newmont’s proposed Red Chris Block Cave, linking mine funding to British Columbia’s North Coast Transmission Line. The deal also includes C$3.9B for BC Hydro’s first two stages. Red Chris needs up to 145 MW; the expansion could add ~14 years of mine life and ~1,800 construction jobs, according to Newmont.

$NEMMedAI 8/10

British Columbia critical minerals push faces delivery test: PwC

A PwC Canada report says British Columbia and Yukon could lose ground in critical minerals supply unless they speed mine construction, power buildout and permitting. PwC’s BC Mine 2025 notes metallurgical coal fell to <50% of BC mining revenue in 2024 from >60% in 2023, while copper rose to 25% from 19%. It cites demand driven by industrial policy and energy security, and highlights infrastructure constraints.

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$SHAZMed

What SharonAI (SHAZ) Said on Its Q3 Earnings Call

SharonAI (SHAZ) reported Q3 earnings, highlighting a $1.32B agreement and new contracts totaling $1.17B. The company terminated a $373M contract due to credit risk. CFO Anuj Goel noted $2.6B in capital secured since December 2025, with $1.3B in cash as of Sept. 30. The NVIDIA AICP program covers 72MW and 40,000 GPUs, with billing expected from Q3 2027. SharonAI plans to fund build-out with secured debt and expects $800M in customer deposits.

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.